These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 4707864)

  • 1. Persistence of immunity following monovalent and combined live measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; Stokes J; Hilleman MR
    Pediatrics; 1973 Mar; 51(3):467-75. PubMed ID: 4707864
    [No Abstract]   [Full Text] [Related]  

  • 2. Persistence of antibody after administration of monovalent and combined live attenuated measles, mumps, and rubella virus vaccines.
    Weibel RE; Buynak EB; McLean AA; Hilleman MR
    Pediatrics; 1978 Jan; 61(1):5-11. PubMed ID: 263873
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Experience with preventive measles, mumps and rubella vaccination in unified Germany].
    Gerike E; Tischer A
    Gesundheitswesen; 1993 Jan; 55(1):38-9. PubMed ID: 8435543
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combined live measles, mumps, and rubella virus vaccines.
    Buynak EB; Weibel RE; Whitman JE; Stokes J; Hilleman MR
    JAMA; 1969 Mar; 207(12):2259-62. PubMed ID: 5818433
    [No Abstract]   [Full Text] [Related]  

  • 5. Combined live measles, mumps, rubella vaccine. Immunological response.
    Krugman S; Muriel G; Fontana VJ
    Am J Dis Child; 1971 May; 121(5):380-1. PubMed ID: 5091532
    [No Abstract]   [Full Text] [Related]  

  • 6. [Measles, mumps and rubella: vaccination rate and seroprevalence in 8th grade students of 8 different sites in Switzerland 1995/96].
    Stohrer-Draxl P; Amstad H; Grize L; Gassner M; Takken-Sahli K; Bourquin C; Braun-Fahrländer C
    Praxis (Bern 1994); 1999 Jun; 88(24):1069-77. PubMed ID: 10420798
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Morbidity, vaccine coverage and immunity against measles, mumps and rubella in a Gallician population from 2 to 5 years old].
    Vázquez Fernández E; López Rois F; Vázquez Carrete JA; Gómez Tato B; Alvarez Ares M
    An Esp Pediatr; 1987 Jul; 27(1):27-31. PubMed ID: 3662251
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combined administration of measles, mumps, rubella, and trivalent oral poliovirus vaccines.
    Krugman RD; Witte JJ; Parkman PD; Herrmann KL; Meyer HM; Wende RD; Meyer BC; Dungca R
    Public Health Rep; 1977; 92(3):220-2. PubMed ID: 866558
    [No Abstract]   [Full Text] [Related]  

  • 9. Studies on live rubella vaccine. V. Quantitative aspects of interference between rubella, measles and mumps viruses in their trivalent vaccine.
    Minekawa Y; Ueda S; Yamanishi K; Ogino T; Takahashi M
    Biken J; 1974 Dec; 17(4):161-7. PubMed ID: 4464833
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Experience with live rubella virus vaccine combined with live vaccines against measles and mumps.
    Smorodintsev AA; Nasibov MN; Jakovleva NV
    Bull World Health Organ; 1970; 42(2):283-9. PubMed ID: 5310140
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Administration of measles-mumps-rubella vaccination with other childhood schedule vaccines.
    Heath TC; Burgess MA; O'Brien ED
    Commun Dis Intell; 1998 Aug; 22(8):159. PubMed ID: 9735551
    [No Abstract]   [Full Text] [Related]  

  • 12. [Field trial with a new human diploid cell vaccine (HDCV) against measles, mumps and rubella].
    Just M; Berger R; Glück R; Wegmann A
    Schweiz Med Wochenschr; 1985 Nov; 115(48):1727-30. PubMed ID: 4081704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Sero-epidemiologic study of measles, rubella and mumps in the infantile population of Salamanca].
    Sáenz González MC; Núñez Mateos JC; Rodrigo Sánchez N; Martín Sánchez AM
    An Esp Pediatr; 1992 Apr; 36(4):293-7. PubMed ID: 1605414
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Protection of mumps in children with various underlying diseases: application of a live attenuated mumps and trivalent measles-rubella-mumps (MRM) vaccines in these children.
    Kanesaki T; Baba K; Tsuda N; Yabuuchi H; Yamanishi K; Takahashi M
    Biken J; 1986 Dec; 29(3-4):63-71. PubMed ID: 3304276
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Prevalence of antibodies and vaccination against measles, mumps and rubella in Polish population].
    Janaszek-Seydlitz W; Bucholc B; Wysokińska T; Górska P; Gniadek G
    Przegl Epidemiol; 2003; 57(2):281-8. PubMed ID: 12910596
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Vaccination rate for triple measles-rubella-mumps vaccine in Empoli Val d'Elsa area health district U.S.L. 11, Tuscany Region].
    Salvadori P
    Ann Ig; 1998; 10(1):19-24. PubMed ID: 9616974
    [No Abstract]   [Full Text] [Related]  

  • 17. [Immunity to measles, mumps and rubella in children vaccinated with triple viral vaccine].
    Pisón Garcés FJ; Galbe Sánchez-Ventura J; Arcauz Eguren P; Aguirre y Dabán C; Mengual Gil J; Larrad Mur L
    Aten Primaria; 1995 Mar; 15(4):235-7. PubMed ID: 7703334
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mumps vaccination.
    Hilleman MR
    Mod Trends Med Virol; 1970; 2(0):241-61. PubMed ID: 5527958
    [No Abstract]   [Full Text] [Related]  

  • 19. [Age-related seroprevalence of measles, mumps and rubella antibodies in 1996].
    Zäch K; Nicoara C; Germann D; Matter L
    Schweiz Med Wochenschr; 1998 Apr; 128(17):649-57. PubMed ID: 9622837
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Measurement of immunity following live mumps (5 years), measles (3 years), and rubella (2 and one-half years) virus vaccines.
    Weibel RE; Buynak EB; Stokes J; Hilleman MR
    Pediatrics; 1972 Mar; 49(3):334-41. PubMed ID: 5010464
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.